CAJ | 학술논문

目的：观察参芪扶正注射液联合吉西他滨和顺铂（gemcitabine&cisplatin,PG）方案治疗非小细胞肺癌（non-small cell lung cancer，NSCLC）的疗效。方法选择2011年8月～2013年8月在上海交通大学附属第六人民医院南院就诊的NSCLC 76例患者，随机分为观察组和对照组，每组38例。对照组予以吉西他滨和顺铂治疗，观察组在对照组的基础上予以参芪扶正注射液治疗。观察2组治疗后的总有效率、疾病控制率、生活质量和不良反应发生率。结果观察组的总有效率为47.37%，对照组的总有效率为42.11%，2组的总有效率差异无统计学意义；而观察组的疾病控制率为81.58%明显高于对照组的57.89%，差异有统计学意义（χ2=3.990，P<0.05）。观察组的生活质量改善率为60.53%明显优于对照组的31.58%，两组差异有统计学意义（χ2=5.296，P<0.05）。观察组的白细胞（χ2=4.491，P<0.05）和血小板（χ2=4.491，P<0.05）减少发生率明显低于对照组，而两组的肝功能损害和胃肠道反应差别无统计学意义。结论参芪扶正注射液有助于提高PG方案治疗NSCLC的疗效，并对化疗药物的毒副作用具有一定的缓解作用。
목적：관찰삼기부정주사액연합길서타빈화순박（gemcitabine&cisplatin,PG）방안치료비소세포폐암（non-small cell lung cancer，NSCLC）적료효。방법선택2011년8월～2013년8월재상해교통대학부속제륙인민의원남원취진적NSCLC 76례환자，수궤분위관찰조화대조조，매조38례。대조조여이길서타빈화순박치료，관찰조재대조조적기출상여이삼기부정주사액치료。관찰2조치료후적총유효솔、질병공제솔、생활질량화불량반응발생솔。결과관찰조적총유효솔위47.37%，대조조적총유효솔위42.11%，2조적총유효솔차이무통계학의의；이관찰조적질병공제솔위81.58%명현고우대조조적57.89%，차이유통계학의의（χ2=3.990，P<0.05）。관찰조적생활질량개선솔위60.53%명현우우대조조적31.58%，량조차이유통계학의의（χ2=5.296，P<0.05）。관찰조적백세포（χ2=4.491，P<0.05）화혈소판（χ2=4.491，P<0.05）감소발생솔명현저우대조조，이량조적간공능손해화위장도반응차별무통계학의의。결론삼기부정주사액유조우제고PG방안치료NSCLC적료효，병대화료약물적독부작용구유일정적완해작용。
Objective To observe the shenqifuzheng injection (SFI) combined with PG therapy (gemcitabine and cisplatin) in patients with non-small cell lung cancer (NSCLC). Method 76 patients with NSCLC were selected from August 2011 to August 2013 and randomly divided into observation group and control group. Each group had 38 cases. The control group received gemcitabine and cisplatin, observation group were gave SFI on the basis of control group. The total efficiency, disease control rate, quality of life and incidence of adverse reactions were observed after treatment in each group. Results The total effective rate was 47.37%in observation group , 42.11%in control group, there was no significant difference between two groups. The disease control rate in observation group was 81.58%higher than 57.89%in control group, the difference was statistically significant (χ2=3.990, P<0.05). The improvement rate in quality of life was 60.53%in observation group better than 31.58%in the control group , the difference was statistically significant (χ2=5.296, P<0.05).The decrease incidence of white blood cell (χ2=4.491, P<0.05) and platelets (χ2=4.491, P<0.05) in observation group were significantly lower compared with the control group, while, there were no difference of liver damage and gastrointestinal reactions between two groups. Conclusion SFI is helpful to improve the efficacy of PG therapy in patients with NSCLC and relieve the side effects of chemotherapy.